Bioverativ Inc Stock

Stocks

18-04-27	Sanofi : sees new acquisitions and drugs reviving growth	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-29	Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	RE
18-03-28	Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	RE
18-02-15	Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	RE
18-02-07	Ablynx : Sanofi's return to profit growth this year slower than hoped	RE
18-01-29	Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	RE
18-01-22	Stocks hit record as senators reach deal to end shutdown	RE
18-01-22	Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	RE
18-01-22	Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE
18-01-22	Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	RE
18-01-22	Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	RE

18-03-06	Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	BU
18-02-14	Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	BU
18-02-13	Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	BU
18-01-24	The Law Offices of Vincent Wong : Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi	BU
18-01-24	WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	PR

18-03-28	Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril
18-03-08	Sanofi finalise l'acquisition de Bioverativ
18-03-08	Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse
18-02-23	Sanofi : franchit une étape dans son offre sur Bioverativ
18-02-07	Sanofi: Amélioration attendue en 2018 plus lente que prévu

Manager	Title	Age	Since
Brian Foard PSD	President	-	-
Timothy J.R. Harris PRN	Corporate Officer/Principal	-	-
Joann Nestor SEC	Corporate Secretary	-	-

Director	Title	Age	Since
Philippe Sauvage BRD	Director/Board Member	49	2018-03-07
Brian Foard BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOVERATIV INC	-.--%	+0.30%	-	-	0
WUXI APPTEC CO., LTD.	-2.01%	-7.86%	+60.74%	+70.97%	70.44B
ARGENX SE	+3.84%	-11.02%	+8.59%	+57.43%	50.31B
LONZA GROUP AG	+3.35%	+1.42%	+11.85%	+40.01%	47.51B
IQVIA HOLDINGS INC.	+0.51%	+1.51%	+27.96%	+31.43%	42.91B
REVOLUTION MEDICINES, INC.	+2.70%	-3.66%	+307.41%	+547.01%	40.39B
BEONE MEDICINES AG	+0.69%	-3.44%	+9.52%	+96.59%	39.69B
CELLTRION, INC.	+0.06%	-2.02%	+11.25%	+43.27%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.52%	-8.54%	+37.67%	+0.98%	26.8B
BIONTECH SE	-0.39%	-6.92%	-13.60%	-14.40%	22.36B
Average	+0.82%	-5.11%	+51.26%	+97.03%	41.22B
Weighted average by Cap.	+0.94%	-4.90%	+54.76%	+102.68%

Employees

Sector